Document is current

Article History

Accepted: 3 September 2025

First Online: 27 September 2025

Declarations

:

: OC is an employee of the University of Sydney and was previously an employee of UNSW and has an adjunct appointment at UNSW; MB is a higher degree research student at UNSW and Medical Director at Medwise Consulting. CS is a current employee of AbbVie. AW is a freelance consultant, Non-executive Director of Faciobiotherapies and was previously an employee of Servier, Abbott, AbbVie, GSK, Gilead Sciences and Bayer. SM is the Medical Director of Amicus Therapeutics Pty Ltd. NA is an employee of Amgen. DT is an employee of the University of Sydney and a director of Axis Health Co Pty Ltd. He was previously Head of APAC information and Technology at Roche. VE is an affiliate of the University of Sydney and Chief Medical Officer at Qbiotics. She was previously an employee at Amgen. Views of all authors are their own and do not necessarily reflect those of their organisations.

: Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

: Not a clinical trial.

: Not a clinical trial.

: Not a clinical trial.

: Not applicable.

: AW, OC, MB and CS wrote the manuscript. All authors have reviewed, edited and approved the final submitted manuscript and agree to be accountable for the work. We acknowledge the assistance of ChatGPT for editing of the final manuscript.